Keio University in Japan has announced that it has started a human clinical trial of anti-aging substances in cooperation with the University of Washington in the United States to confirm its efficacy and safety. This substance has been shown to be effective in experimental mice.
Keio University and the University of Washington have collaborated recently to conduct human clinical trials of the anti-aging substance nicotinamide mononucleotide (NMN) for the first time in the world. NMN plays an important role in human cell energy production. It is involved in the synthesis of nicotinamide adenine dinucleotide (NAD) in cells, and NAD is an important coenzyme for cell energy conversion. NMN can only be synthesized in the laboratory, making it difficult to achieve mass production.
Earlier experiments have confirmed that NMN can increase NAD in various organs of rats, thereby inhibiting aging of nerves and blood vessels, and improving symptoms of diabetes. NMN and NAD are produced in the human body, but as they age, their levels in various organs are reduced. It is unclear what effect NAM intake will have on human organs.
According to the plan, the research team will allow 10 healthy male testers aged 40 to 60 to ingest unequal amounts of NMN, and confirm the safety of NMN intake and its absorption in the human body through physiological examinations and blood tests.
The team believes that if it is possible to confirm that ingestion of NMN is safe and effective through this study, it is possible to use NMN in the future to prevent and treat diseases associated with aging.
Wireless Ballbar For Machine Tool,Machine Tool Performance Verification,Ballbar For Sale,Wireless Ballbar
Automated Precision Inc. , https://www.apiasean.com